Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2019
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.Frontiers in immunology · 2022Pooled it
- Clinical impact of infused CD3-positive cell dose in unrelated peripheral blood stem cell transplantation.International journal of hematology · 2026Article
- Article
- Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation.Clinical & translational immunology · 2024Article
- The Impact of Graft CD3Journal of hematology · 2023Article
- Characterization and Function of Cryopreserved Bone Marrow from Deceased Organ Donors: A Potential Viable Alternative Graft Source.Transplantation and cellular therapy · 2023Article
- High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide.Bone marrow transplantation · 2020Article
- Impact of Lymphocyte Subsets of Grafts on the Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation.Cell transplantationArticle
- Article
Corrections and comments
- Commented on by
Authors and funding
63 authors at 20 institutions in 10 countries.
Ayman SaadDivision of Hematology, The Ohio State University, Columbus, Ohio.
Lawrence LambUniversity of Alabama at Birmingham, Birmingham, Alabama.
Tao WangDivision of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael T HemmerCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Stephen SpellmanCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be the Match, Minneapolis, Minnesota.
Daniel CourielUtah Blood and Marrow Transplant Program, Salt Lake City, Utah.
Amin AlousiDepartment of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Joseph PidalaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.
Hisham Abdel-AzimDivision of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Vaibhav AgrawalDivision of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Mahmoud AljurfOncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Amer M BeitinjanehUniversity of Miami, Miami, Florida.
Vijaya Raj BhattThe Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
David BuchbinderDivision of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.
Michael ByrneDivision of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Mitchell CairoDivision of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, New York, New York.
Paul CastilloUF Health Shands Children's Hospital, Gainesville, Florida.
Saurabh ChhabraDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Miguel Angel DiazDepartment of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
Shatha FarhanHenry Ford Hospital Bone Marrow Transplant Program, Detroit, Michigan.
Yngvar FloisandThe National Hospital, Oslo, Denmark.
Hadar A FrangoulChildren's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, Tennessee.
Shahinaz M GadallaDivision of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, Maryland.
James GajewskiConsultant at Lu Daopei Hospital, Beijing, China.
Robert Peter GaleHematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
Manish GandhiDivision of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota.
Usama GergisHematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
Betty Ky HamiltonBlood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Peiman HemattiDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, Kentucky.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Abraham S KanateOsborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia.
Pooja KhandelwalDivision of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Aleksandr LazaryanDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.
Margaret MacMillanUniversity of Minnesota Blood and Marrow Transplant Program, Pediatrics, Minneapolis, Minnesota.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Rodrigo MartinoDivision of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Parinda A MehtaDivision of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Sagar S PatelBlood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, Ohio.
Muna QayedDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Hemalatha G RangarajanDepartment of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, Ohio.
Ran ReshefBlood and Marrow Transplantation Program and Columbia Center for Translational Immunobiology, Columbia University Medical Center, New York, New York.
Olle RingdenTranslational Cell Therapy Research, Karolinska Institute, Stockholm, Sweden.
Bipin N SavaniDivision of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Harry C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.
Kirk R SchultzDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, Britich Columbia, Canada.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Brian C ShafferMemorial Sloan Kettering Cancer Center, New York, New York.
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
Takanori TeshimaHokkaido University Hospital, Sapporo, Japan.
Alvaro Urbano-IspizuaDepartment of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, and Josep Carreras Institute of Research, Barcelona, Spain.
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
Ravi VijDivision of Hematology and Oncology, Washington University School of Medicine, St Louis, Missouri.
Edmund K WallerDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Basem WilliamDivision of Hematology, The Ohio State University, Columbus, Ohio.
Baldeep WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
Jean A YaredBlood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Lolie C YuDivision of Hematology/Oncology and HSCT, Center for Cancer and Blood Disorders, Children's Hospital/Louisiana State University Medical Center, New Orleans, Louisiana.
Mukta AroraDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota. Electronic address: arora005@umn.edu.
Shahrukh HashmiOncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Medical College of Wisconsin · USMoffitt Cancer Center · USCincinnati Children's Hospital Medical Center · USCleveland Clinic · USEmory University · USMayo Clinic · USThe Ohio State University · USVanderbilt University Medical Center · USBaylor College of Medicine · USBeijing Dao Pei Hospital · CNCentre Hospitalier Universitaire de Grenoble · FRChildren’s Hospital at TriStar Centennial · USChildren's Hospital of Orange County · USColumbia University Irving Medical Center · USDokkyo Medical University · JPHenry Ford Hospital · USHokkaido University Hospital · JPHospital de Sant Pau · ESHospital Infantil Universitario Niño Jesús · ESImperial College London · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MGenetic Epidemiology of Telomere Maintenance and Cancer EtiologyZIACP010190 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$10.2MUsing donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantationR01AI145231 · NIAID · EMORY UNIVERSITY · PI WALLER, EDMUND K · 2020 to 2024
$3.6MUsing donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantationR01CA188523 · NCI · EMORY UNIVERSITY · PI WALLER, EDMUND K · 2014 to 2018
$1.6MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA188523NCI NIH HHS U24 CA076518NHLBI NIH HHS U24 HL138660NIAID NIH HHS R01 AI145231
Abstract
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations. Correlative analysis was performed between CD3
Indexed as
CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesGraft vs Host DiseaseLeukemiaMyelodysplastic SyndromesPeripheral Blood Stem Cell TransplantationAcute DiseaseAdolescentAdultAllograftsCD4-CD8 RatioDisease-Free SurvivalFemaleHLA AntigensHumansMaleHLA AntigensAllogeneicGVHD doseT cellTransplantation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.